Table 3 Number of cardiovascular events in subjects in study 1 (A) and study 2 (B)
OHAs (Administration of one medicine) | Cardiovascular events (patients) | Cardiac events (patients) | Stroke (patients) | Analysis |
|---|---|---|---|---|
(A) | ||||
SU | 80 | 71 | 10 | 629 |
Biguanide | 84 | 76 | 10 | 1305 |
α-GI | 63 | 58 | 7 | 592 |
TZD | 35 | 29 | 6 | 351 |
Glinide | 21 | 19 | 3 | 223 |
DPP-4 inhibitor | 87 | 80 | 8 | 995 |
(B) | ||||
SU | 58 | 53 | 6 | 228 |
Biguanide | 47 | 48 | 4 | 325 |
α-GI | 40 | 40 | 3 | 203 |
TZD | 26 | 24 | 3 | 140 |
Glinide | 14 | 14 | 1 | 70 |
DPP-4 inhibitor | 56 | 57 | 3 | 307 |